AVEF

Avecho Biotechnology Ltd. (AVEFF)

Market Closed
6 Jun, 20:00
OTC PINK OTC PINK
$
0. 00
-0.01
-74.14%
$
11.42M Market Cap
- P/E Ratio
0.67% Div Yield
0 Volume
0 Eps
$ 0.02
Previous Close
Day Range
0 0
Year Range
0 0.02

Summary

AVEFF closed Friday lower at $0, a decrease of 74.14% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, AVEFF stock gained 275%.
AVEFF is not paying dividends to its shareholders.
The last earnings report, released on May 29, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).
Want to track AVEFF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

AVEFF Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Avecho Biotechnology Ltd. (AVEFF) FAQ

What is the stock price today?

The current price is $0.00.

On which exchange is it traded?

Avecho Biotechnology Ltd. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is AVEFF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 11.42M.

Has Avecho Biotechnology Ltd. ever had a stock split?

No, there has never been a stock split.

Avecho Biotechnology Ltd. Profile

Biotechnology Industry
Healthcare Sector
Dr. Paul Gavin BSc (Hons), Ph.D. CEO
OTC PINK Exchange
AU0000047441 ISIN
AU Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Avecho Biotechnology Limited is a distinguished biotechnology firm rooted in Clayton, Australia, focusing on the invention and market introduction of products beneficial for both human and animal health. Utilizing its unique drug delivery system alongside Tocopherol Phosphate Mixture (TPM), the company excels in the biotechnology sector. Established in 1992, Avecho operates across two main segments: Production and Human Health, underscoring its versatility and commitment to improving health outcomes. Through strategic collaborations, such as with the Lambert Initiative at the University of Sydney for osteoarthritis treatment, Avecho underscores its devotion to advancing medical research and delivering innovative health solutions.

Products and Services

  • TPM and Vital ET Products:
  • A cornerstone of Avecho's product lineup, TPM (Tocopherol Phosphate Mixture) and Vital ET products are designed for drug delivery and cosmetic formulations. These products leverage Avecho's proprietary delivery system to enhance the effectiveness and stability of active ingredients, offering advancements in topical and systemic therapeutics and in cosmetic applications.

  • Human Health Portfolio:
  • This portfolio features a variety of delivery mechanisms for pharmaceutical products, including gels, injectables, and patches. Aimed at improving patient outcomes and experience, these delivery systems are developed to ensure precise dosing, enhance drug absorption, and provide user-friendly applications for medications, addressing a range of health conditions.

  • Feed Additive Products:
  • With an eye on the agricultural sector, Avecho is also developing feed additive products intended to boost feed efficiency and the overall health of livestock animals. These innovations underscore the company's commitment to contributing towards sustainable livestock management by enhancing nutritional intake and promoting healthier livestock, which is vital for the agriculture industry.

Contact Information

Address: 2A Westall Road
Phone: 61 3 9002 5000